Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
Briya announced that its global data network now includes over 120 million patient records, expanding coverage to Latin America and the UK to support AI-driven medical research through its Briya AIRE research engine.
Spirographic AI has introduced a new polypharmacology platform capable of predicting drug targets and side effects across multiple organ systems with unprecedented accuracy.
Tuesday Health announced a partnership with Humana to provide value-based palliative care for Texans living with serious illness, launching June 1, 2026.
Wavelet Medical has partnered with Aegis Ventures to commercialize an AI-powered fetal EEG monitoring platform that detects brain distress in real time, supported by $7 million in seed funding.
Accuity has appointed Cindy Klain as Chief Product and Strategy Officer to oversee product management and corporate strategy, bringing experience from Optum, Change Healthcare, and GE Healthcare.
Technogym has announced a multi-year partnership with Google Cloud to integrate generative AI technologies into its Technogym AI Ecosystem, enhancing both user and operator experiences through hyper-personalized training and optimized business tools.
Harbinger Health has announced RESOLVE, a new category of blood-based multi-cancer detection tests aimed at reducing diagnostic delays and improving clinical decision-making, with commercial availability expected in late 2026.
Kazia Therapeutics has licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, featuring an AI-integrated discovery engine and lead candidate MSETC aimed at overcoming tumor immune resistance.
Senhwa Biosciences has signed an MOU with GEM Yield Bahamas for up to NT$500 million in funding to support its AI-enabled drug discovery and global expansion.
Function Health has acquired Getlabs to enable its members to schedule at-home or in-office lab testing, expanding access to health data through mobile healthcare services.
Decoy Therapeutics announced it is entering a key phase toward clinical development, supported by an AI collaboration with Quantori and Google Cloud to accelerate antiviral candidate discovery and optimization.
ProQR Therapeutics has announced a partnership with Ginkgo Bioworks to use its autonomous lab for AI-enabled RNA drug discovery and the creation of an AI Advisory Board to guide its Axiomer platform strategy.
L7 Informatics has introduced L7|SYNAPSE, an agentic AI layer built on its L7|ESP platform, designed to enable secure, context-aware AI interactions in regulated scientific environments.
Jetstream Venture Fund announced new investments in Surf Therapeutics and Hill Research, expanding its healthtech and AI portfolios. The fund's backing of Hill Research marks its first dedicated AI investment, targeting automation in clinical pharmaceutical research.
Onix has launched Personal Intelligence, a new AI platform built on expert knowledge rather than general internet data. The system, debuting in the health and wellness sector, provides private, end-to-end encrypted guidance from licensed experts, with user data stored locally.
Lumonus has announced a collaboration with Memorial Sloan Kettering Cancer Center to integrate and co-develop the ECHO optimization engine for automated radiation therapy treatment planning, aiming to improve efficiency and plan quality.
Rubrum Advising has introduced Rubrum Solutions, an AI-native platform that processes structured and unstructured healthcare data to streamline prior authorization, benefits verification, and clinical workflows.
BoomerangFX announced that its AUVIA AI Clinic Co-Pilot now handles over 1,000 autonomous patient consultations monthly, marking a milestone in AI-driven healthcare operations across global markets.
XRP Healthcare announced that its new utility token, XRPHAI, will list on MEXC on April 8, 2026, followed by the launch of a rewards system on April 9. The token powers the XRPH AI App, which rewards users for verified health-related activities.
AvenCell Therapeutics has dosed the first patient in its Phase I QUADvance trial testing AVC-203, a CRISPR-engineered allogeneic CAR-T therapy targeting CD19 and CD20 in relapsed or refractory B-cell malignancies.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
